Pharmadrug (TSE:PHRX) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
PharmaDrug’s Sairiyo Therapeutics has successfully completed a stability study of its reformulated cepharanthine, PD-001, paving the way for its Phase 1 clinical trial as a potential treatment for viral infectious diseases. This development marks a significant step forward in leveraging cepharanthine’s improved oral bioavailability for more effective therapeutic applications. The completion of the study allows the company to proceed with manufacturing and clinical trial preparations in Australia.
For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.